CAT 5001

Drug Profile

CAT 5001

Alternative Names: Anti-Mesothelin Immunotoxin; CAT-5001; SS 1P; SS1(dsFv)-PE38

Latest Information Update: 17 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA)
  • Class Antineoplastics; Immunotoxins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mesothelioma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 29 Oct 2007 Cambridge Antibody Technology has been acquired and merged into MedImmune
  • 27 Jul 2006 CAT 5001 has been licensed to Cambridge Antibody Technology worldwide
  • 30 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top